The big business bet on psychedelic drugs
The Decibel
00:00
Breakthrough Designation for Psychedelic Drugs
The chapter explores the FDA granting breakthrough designation to psychedelic drugs like LSD and psilocybin for treating mental health disorders, signaling a shift towards recognizing them as legitimate pharmaceutical treatments. It focuses on Canadian companies, MindMed and Cybin, and their research on these substances, highlighting promising trial results such as high remission rates and sustained symptom reduction. While there is growing interest in psychedelic-assisted therapies, further research and regulatory approval are necessary before widespread use.
Transcript
Play full episode
